Evidence map›Paper›PMID 25750999›Full record

ArticleHuman vaccines & immunotherapeutics2015

Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Abel E Vasquez, Ricardo A Manzo, Daniel A Soto, Magaly J Barrientos, Aurora E Maldonado, Macarena Mosqueira, Anastasia Avila, Jorge Touma, Elsa Bruce, Paul R Harris and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Abel E Vasqueza Department of Biotechnology ; Instituto de Salud Pública de Chile ; Ñuñoa , Santiago , Chile.
Ricardo A Manzo
Daniel A Soto
Magaly J Barrientos
Aurora E Maldonado
Macarena Mosqueira
Anastasia Avila
Jorge Touma
Elsa Bruce
Paul R Harris
Alejandro Venegas
Instituto de Salud Pública de Chile · CLDiego Portales University · CLIndiana University School of Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Neisseria meningitidis outer membrane protein PorA from a Chilean strain was purified as a recombinant protein. PorA mixed with AbISCO induced bactericidal antibodies against N. meningitidis in mice. When PorA was fused to the Helicobacter pylori HpaA antigen gene, the specific response against H. pylori protein increased. Splenocytes from PorA-immunized mice were stimulated with PorA, and an increase in the secretion of IL-4 was observed compared with that of IFN-γ. Moreover, in an immunoglobulin sub-typing analysis, a substantially higher IgG1 level was found compared with IgG2a levels, suggesting a Th2-type immune response. This study revealed a peculiar behavior of the purified recombinant PorA protein per se in the absence of AbISCO as an adjuvant. Therefore, the resistance of PorA to proteolytic enzymes, such as those in the gastrointestinal tract, was analyzed, because this is an important feature for an oral protein adjuvant. Finally, we found that PorA fused to the H. pylori HpaA antigen, when expressed in Lactococcus lactis and administered orally, could enhance the antibody response against the HpaA antigen approximately 3 fold. These observations strongly suggest that PorA behaves as an effective oral adjuvant.

Indexed as

Adhesins, BacterialAdjuvants, ImmunologicAdministration, OralAnimalsAntibodies, BacterialFemaleHelicobacter pyloriImmunoglobulin GInterferon-gammaInterleukin-4Lactococcus lactisLeukocytes, MononuclearMice, Inbred BALB CPorinsRecombinant Fusion ProteinsSerumadhesin A, HelicobacterAdhesins, BacterialAdjuvants, ImmunologicAntibodies, BacterialImmunoglobulin GInterferon-gammaInterleukin-4porin protein, NeisseriaPorinsRecombinant Fusion ProteinsAbISCO TM-100® adjuvantAbISCO TM-100®, adjuvant based on saponinHelicobacter pylori antigenhybrid PorA antigensimmunostimulant complex matrixLAL, limulus amebocyte lysatemeningococcal B porin antigenoral immunizationrecombinant PorA

Identifiers

PMID25750999
PMCPMC4514328
OpenAlexW1492695496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.